JP2024535351A5 - - Google Patents

Info

Publication number
JP2024535351A5
JP2024535351A5 JP2024518361A JP2024518361A JP2024535351A5 JP 2024535351 A5 JP2024535351 A5 JP 2024535351A5 JP 2024518361 A JP2024518361 A JP 2024518361A JP 2024518361 A JP2024518361 A JP 2024518361A JP 2024535351 A5 JP2024535351 A5 JP 2024535351A5
Authority
JP
Japan
Prior art keywords
composition according
item
approximately
dried composition
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/013508 external-priority patent/WO2023048758A1/en
Publication of JP2024535351A publication Critical patent/JP2024535351A/ja
Publication of JP2024535351A5 publication Critical patent/JP2024535351A5/ja
Pending legal-status Critical Current

Links

JP2024518361A 2021-09-22 2022-01-24 乾燥ナノ粒子組成物 Pending JP2024535351A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163247172P 2021-09-22 2021-09-22
US63/247,172 2021-09-22
US202263297449P 2022-01-07 2022-01-07
US63/297,449 2022-01-07
PCT/US2022/013508 WO2023048758A1 (en) 2021-09-22 2022-01-24 Dried nanoparticle compositions

Publications (2)

Publication Number Publication Date
JP2024535351A JP2024535351A (ja) 2024-09-30
JP2024535351A5 true JP2024535351A5 (cg-RX-API-DMAC7.html) 2025-01-31

Family

ID=85721060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518361A Pending JP2024535351A (ja) 2021-09-22 2022-01-24 乾燥ナノ粒子組成物

Country Status (7)

Country Link
US (2) US12233160B2 (cg-RX-API-DMAC7.html)
EP (1) EP4404919A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024535351A (cg-RX-API-DMAC7.html)
KR (1) KR20240088845A (cg-RX-API-DMAC7.html)
AU (1) AU2022352486A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232566A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023048758A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024535352A (ja) * 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Sars-cov-2 rnaワクチン組成物および使用方法
KR20260100690A (ko) * 2023-10-20 2026-06-30 일라이 릴리 앤드 캄파니 중추 신경계 전체에 걸쳐 치료제를 전달하기 위한 나노입자 및 그의 제형
GB202408358D0 (en) * 2024-06-11 2024-07-24 Uncommon Bio Ltd Methods and compositions for transfecting cells
WO2026098357A1 (en) * 2024-11-11 2026-05-15 Kudo Biotechnology, Inc. Freeze-dried nucleic acid-loaded lipid nanoparticle and reconstitution method thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
WO2001021810A1 (en) 1999-09-17 2001-03-29 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU2002305914A1 (en) 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
WO2004055216A2 (en) 2002-12-13 2004-07-01 Fox Chase Cancer Center Replication of hepatitis c virus in non-hepatic epithelial and mouse hepatic cells
CA2539490A1 (en) 2003-09-18 2005-03-24 Genmab A/S Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
TWI388344B (zh) * 2005-08-23 2013-03-11 Celsion Corp 儲存奈米微粒調合物之方法
US9393215B2 (en) * 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008124647A2 (en) 2007-04-04 2008-10-16 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
US9446150B2 (en) 2007-10-09 2016-09-20 Washington University Particles for imaging
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
AU2009280803B2 (en) * 2008-07-23 2013-10-31 Bharat Serums And Vaccines Ltd. Stable injectable oil-in-water Docetaxel nanoemulsion
EP2401365B1 (en) 2009-02-24 2016-04-27 The Scripps Research Institute Reengineering mrna primary structure for enhanced protein production
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
CN102811743B (zh) * 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
US8722853B2 (en) 2010-06-10 2014-05-13 University Of Washington Through Its Center For Commercialization Methods and systems for adenovirus interaction with desmoglein 2 (DSG2)
US9555136B2 (en) 2010-06-21 2017-01-31 University Of Washington Through Its Center For Commercialization Coated magnetic nanoparticles
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
US9101669B2 (en) 2012-01-31 2015-08-11 Postech Academy-Industry Foundation Self-assembed conjugate and use thereof
EP4299138A3 (en) 2012-08-03 2024-08-14 Access to Advanced Health Institute Compositions and methods for treating an active mycobacterium tuberculosis infection
US20160000886A1 (en) 2013-02-22 2016-01-07 President And Fellows Of Harvard College Nanostructured active therapeutic vehicles and uses thereof
US9775894B2 (en) 2013-07-09 2017-10-03 University Of Washington Through Its Center For Commercialization Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
RU2546249C2 (ru) 2013-08-07 2015-04-10 Силезиа Груп Пте. Лтд. Композиция для усиления экспрессии трансгена в эукариотических клетках и способ увеличения продукции целевого белка, кодируемого трансгеном
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
SG11201705820UA (en) 2015-01-16 2017-08-30 Nat Inst Advanced Ind Science & Tech Gene expression system using stealthy rna, and gene introduction/expression vector including said rna
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
CN106176599A (zh) 2015-05-06 2016-12-07 江苏天士力帝益药业有限公司 一种卡巴他赛脂肪乳注射剂及其制备方法
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
KR20180082457A (ko) * 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
CN106880592B (zh) * 2015-12-15 2021-04-06 江苏恒瑞医药股份有限公司 一种曲贝替定的纳米乳及其制备方法
DE102017206254B4 (de) 2016-04-13 2024-07-11 Dialog Semiconductor (Uk) Limited DC-DC-Umwandlung für Mehrzellen-Batterien
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ,インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
RU2761870C2 (ru) 2016-05-16 2021-12-13 Инфекшес Дизис Рисёрч Инститьют Состав, содержащий агонист tlr, и способы применения
KR102483033B1 (ko) 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
EP3458088A2 (en) 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
EP3463300A1 (en) 2016-06-01 2019-04-10 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
EP3468537A1 (en) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018022957A1 (en) 2016-07-29 2018-02-01 Tarveda Therapeutics, Inc. T cell binding conjugates and methods of use
KR20180025701A (ko) 2016-09-01 2018-03-09 (주)아모레퍼시픽 특정 siRNA을 포함하는 멜라닌 증진용 조성물
WO2018053294A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
ES2993107T3 (en) 2016-10-17 2024-12-23 Janssen Pharmaceuticals Inc Recombinant virus replicon systems and uses thereof
WO2018081638A1 (en) 2016-10-27 2018-05-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
WO2018147710A1 (ko) 2017-02-13 2018-08-16 단디바이오사이언스 주식회사 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도
AU2018285694B2 (en) * 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
US12065649B2 (en) 2018-01-09 2024-08-20 Vanderbilt University Pattern recognition receptor agonist prodrugs and methods of use thereof
KR20200111729A (ko) 2018-01-19 2020-09-29 얀센 파마슈티칼즈, 인코포레이티드 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
AU2019215191B2 (en) 2018-02-02 2025-08-14 University Of Washington Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling
KR20210104835A (ko) 2018-12-19 2021-08-25 누클레인, 엘엘씨 분자 진단을 위한 장치 및 방법
WO2020146690A1 (en) 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Methods for in vitro evolution of rna replicons
US11406699B2 (en) 2019-03-22 2022-08-09 George Mason University Alphavirus and compositions, methods, and kits related thereto
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
GB201908729D0 (en) 2019-06-18 2019-07-31 Imp College Innovations Ltd RNA construct
EP4004037A1 (en) 2019-07-26 2022-06-01 Vanderbilt University Human monoclonal antibodies to enterovirus d68
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
JP2022550454A (ja) 2019-10-02 2022-12-01 ユニバーシティ オブ ワシントン B型肝炎ウイルス感染の治療のための組成物及び方法
WO2021072112A1 (en) 2019-10-09 2021-04-15 Hdt Bio Corp. Detection of desmoglein-2 in cancers of epithelial origin
AU2020367786A1 (en) 2019-10-14 2022-05-26 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
BR112022016054A2 (pt) 2020-02-14 2022-10-11 Altimmune Inc Composições imunogênicas para coronavírus e usos das mesmas
WO2021178416A1 (en) 2020-03-02 2021-09-10 Heat Biologics, Inc. Immune-mediated coronavirus treatments
US11478543B1 (en) 2020-03-06 2022-10-25 Thomas Jefferson University Coronavirus disease (COVID-19) vaccine
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
TWI891771B (zh) 2020-04-17 2025-08-01 美商Vlp醫療股份有限公司 冠狀病毒疫苗
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
JP2024501949A (ja) 2020-12-23 2024-01-17 アクセス ツー アドバンスト ヘルス インスティチュート ソラネソールワクチンアジュバント及びその調製方法
IN202121031414A (cg-RX-API-DMAC7.html) 2021-07-13 2023-01-13
IN202121038492A (cg-RX-API-DMAC7.html) 2021-08-25 2023-03-03
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
AU2022358446A1 (en) 2021-09-22 2024-04-18 Hdt Bio Corp. Compositions and methods for enhanced protein production

Similar Documents

Publication Publication Date Title
US11433142B2 (en) Compositions and methods for delivery of RNA-lipid nanoparticle complexes encoding for viral RNA polymerase region and protein antigen
JP2023518976A5 (cg-RX-API-DMAC7.html)
US20060008519A1 (en) Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
KR101275837B1 (ko) 당지질들을 이용하여 지질기반 보강제 제형을 안정화시키기 위한 조성물 및 방법
JP2016512226A (ja) 緩衝化アミノアルキルグルコサミニドホスフェート誘導体を含有する組成物及び免疫応答を増強するためのその使用
WO2023062353A1 (en) Nanoparticulate formulation
JP2020002117A (ja) スクアレン含有アジュバント組成物
IL319329A (en) Immunogenic vaccine composition incorporating saponin
US11679163B2 (en) Compositions and methods for delivery of RNA
CA3179062A1 (en) Nanoparticulate formulation
US20250049915A2 (en) Nanoparticulate formulation